The role of the host in the management of patients with mycotic infection is considered. In vivo studies with ketoconazole indicate the importance of the host and the possibility of stimulating host immune mechanisms by an immune modulator.
Introduction
Considerable attention was paid during this symposium to the role of the host in mycotic infections. It becomes increasingly attractive to think that the treatment of mycotic infections might need a dual approach. On the one hand, the germ must be inhibited, on the other hand the host defences might need to be reconstituted.
Antimycotic therapy
There are excellent drugs available for the topical treatment of dermatophytoses and oral or vaginal candidiasis. There is little to improve in this field. In contrast, room is left for drugs that act systemically. The spectrum of griseofulvin is narrow. The advantages and disadvantages of amphotericin B and flucytosine have now been well described. The recently developed intravenous miconazole is safe and effective in a large variety of systemic mycoses. The intravenous route is, however, unpractical for long-term treatment. A drug that can be given orally for long periods of time, has a broad spectrum of activity, readily penetrates body fluids, is safe, and does not induce resistance would be a welcome addition to the still limited armamentarium of systemic antimycotic drugs.
Ketoconazole, which was mentioned earlier by both Borelli et al. (1979) Immunotherapy may be a useful adjunct to antimycotic treatment in such patients. It may also be a useful tool to unravel the mechanisms that are responsible for the recurrent or persistent character of certain mycotic infections.
